NCT02416661View on ClinicalTrials.gov

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

CompletedOBSERVATIONAL
Enrollment

299

Participants

Timeline

Start Date

August 27, 2018

Primary Completion Date

January 15, 2021

Study Completion Date

January 15, 2021

Conditions
Lysosomal Storage DiseasesGaucher DiseaseSphingolipidoses
Trial Locations (8)

10001

University Hospital Center Mother Teresa, Tirana

10100

Children hospital, Rabat

Hopital d'Enfant, Rabat

54600

The Children's Hospital and the Institute of Child Health, Lahore

54642

Aristotle University of Thessaloniki, Ippokration General Hospital, Thessaloniki

560100

Centre for Human Genetics, Bangalore

9103 102

Shaare Zedek Medical Center, Jerusalem

08907

Hospital Universitari de Bellvitge (planta 7.1), Barcelona

All Listed Sponsors
lead

CENTOGENE GmbH Rostock

INDUSTRY

NCT02416661 - Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease | Biotech Hunter | Biotech Hunter